Boston Scientific Corporation (BSX) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $56.96, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -7.3%/30d (confirmed downtrend).
Boston Scientific is a global medical device developer and marketer across MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (ICVT, WATCHMAN, Electrophysiology, CRM, Interventional Oncology) segments, marketing products in 127 countries. International net sales... Read more
Hold if already holding. Not a fresh buy at $56.96, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -7.3%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Score 6.6/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst cluster(8), earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — Boston Scientific Corporation
Latest news
- Boston Scientific Corporation (BSX): Stephen Mandel Opens New Position in Medical Device Firm - Yahoo Finance — Yahoo Finance positive
- Boston Scientific (BSX) stock sinks as market gains: Here's why - MSN — MSN negative
- SHAREHOLDER ALERT Securities Class Action Filed Against Boston Scientific Corporation (BSX) - TMX Newsfile — TMX Newsfile negative
- Stock Market Today, April 22: Boston Scientific Jumps After Q1 Earnings Beat Resets Growth Expectations - The Motley Foo — The Motley Fool positive
- Boston Scientific Slashes Guidance; Why Shares Went Flying - Investor's Business Daily — Investor's Business Daily negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicinternational36%10-K Item 1A: 'International net sales accounted for 36 percent of our global net sales in 2025'
Material Events(8-K, last 90d)
- 2026-02-23Item 5.02LOWBoard increased size from 10 to 12 directors and appointed Catherine R. Smith and Christophe P. Weber effective February 18, 2026. Smith joined Audit and Nominating Committees; Weber joined Compensation and Risk Committees.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $56.96, but acceptable to hold if already in. Reason: Below 200-MA, MA slope -7.3%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Target $76.76 (+34.8%), stop $53.39 (−6.7%), A.R:R 4.7:1. Score 6.6/10, moderate confidence.
Take-profit target: $76.76 (+35.1% upside). Target $76.76 (+34.8%), stop $53.39 (−6.7%), A.R:R 4.7:1. Stop-loss: $53.39.
Below 200-MA, MA slope -7.3%/30d (confirmed downtrend).
Boston Scientific Corporation trades at a P/E of 23.4 (forward 14.9). TrendMatrix value score: 7.2/10. Verdict: Hold.
41 analysts cover BSX with a consensus score of 4.2/5. Average price target: $83.
What does Boston Scientific Corporation do?Boston Scientific is a global medical device developer and marketer across MedSurg (Endoscopy, Urology,...
Boston Scientific is a global medical device developer and marketer across MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (ICVT, WATCHMAN, Electrophysiology, CRM, Interventional Oncology) segments, marketing products in 127 countries. International net sales represent 36% of global revenues with hospitals and clinics as primary customers. A pending $14.5B acquisition of Penumbra, Inc. is expected to close in 2026.